![](https://investorshub.advfn.com/uicon/158678.png?cb=1661594561)
Wednesday, February 24, 2021 10:47:37 PM
I don't think it's quite that black and white.
"The Company signed a non-binding term sheet in August 2018" per a 10K that didn't get published until mid-September.
"In January 2021, Alfasigma notified the Company that the Phase 1 study for the treatment of UP/UPS using Brilacidin in a proprietary Alfasigma formulation was successfully completed. Planning for a Phase 2 clinical trial is underway." Per a 10Q filed yesterday.
He's not always that quick on the draw, even when the news is good.
"suddenly choose to not mention a very favorable peer-review article and a multinational trial start?"
Maybe he doesn't see the peer review as favorably as you do. I'd like to know what "placebo" they are using.
Section 3.5 says:
"The data revealed that brilacidin and favipiravir independently exerted up to 90% and 80% inhibition, respectively, and the extent of inhibition did not increase over that exerted by brilacidin alone when the two drugs were used in combination (Figure 5A)."
You would think that a similar sentence would be included describing a comparison between the independent use of B and remdesivir. I couldn't find one. So we're told that b alone works better than f alone but I found no indication of how b worked versus r in the same experiment.
Assuming I'm not wrong about that I obviously can't be the only one who noticed it. Did you? If such a comparison was absent would it still be a very favorable peer-review article worthy of a press release?
The lack of a PR mentioning the multinational trial start might raise a question or two as well. There's the 106 out of 120 patients in Russia question that couldn't easily be ignored. And as previously mentioned, what will the "placebo" be?
You seem to be convinced that someone doesn't want that information to be made public. What motive could they have for that?
ps. re:
"Everyone can draw their own conclusions."
Duh!
"Good or bad, it's definitely out of the ordinary if Leo chose to do this without a substantial reason."
No doubt about that. But that reason doesn't have to be a good one, like a potential BP partner wants them to lay low. It could be because some things are hard to explain.
“I have had a wonderful time but this wasn't it.”
..........Groucho
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM